News

Astellas UK was suspended from membership of the Association of the British Pharmaceutical Industry (ABPI) with effect from 24 June 2016.  This has been extended for a further 12 months.

Astellas UK and Astellas Europe have brought discredit upon, and reduced confidence in, the pharmaceutical industry, in addition both have been publicly reprimanded. Pfizer Ltd, Novartis Pharmaceuticals UK Ltd and Tor Generics Ltd have brought discredit upon, and reduced confidence in, the pharmaceutical industry.

PMCPA ANNUAL REPORT SHOWS A BUSY YEAR, WITH MORE COMPLAINTS IN 2016 THAN IN THE PREVIOUS TWO YEARS.

The ABPI and NHS England have issued a joint letter setting out the ambition to increase consent rates as quickly as possible for publication of payments to individuals on Disclosure UK. The letter, ​published on 22 December 2017 and signed by ABPI CEO Mike Thompson and NHSE National Director Ian Dodge,​ is now available on the ABPI website. 

Both companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, PharmaMar has been publicly reprimanded and required to issue a corrective statement.

All four companies have brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, Pierre Fabre was publicly reprimanded in one case.

The Consultation closed on 10th October 2018. Many thanks to those who contributed.

The company has brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition Thame Laboratories was required to issue a corrective statement to recipients of the letter at issue.

The report covers details of complaints made in 2017 and considered by the PMCPA in relation to the ABPI Code of Practice for the Pharmaceutical Industry. How many were received, who made them, their outcomes and sanctions

Proposals to amend the ABPI Code of Practice 2016 and the PMCPA Constitution and Procedure were agreed by ABPI members on 4 December 2018.

Disclosure template for 2018 data submissions